Intuitive Surgical (ISRG), based in Sunnyvale, California, develops robotic systems intended to support minimally invasive surgical procedures. The da Vinci platform includes a surgeon’s console, a patient-side cart, a 3-D vision system, the da Vinci Skills Simulator, and Firefly Fluorescence Imaging. Hospitals use these systems to enhance surgical precision and help standardize procedural workflows across a wide range of specialties.
About This Page
Stockmark101.com is a free educational site focused on explaining how stocks and markets work. Company write-ups reflect general market commentary and publicly available information and are used to illustrate business fundamentals and market behavior — not personalized investment advice.
Company Snapshot
| Price | $567 | Category | Aggressive | |
| Market Cap | $203B | Dividend | 0 | 0 |
| P/E Ratio | 75.21 | Analyst Avg | 1-Yr Target | $592 |
| Consensus EPS Estimate | 1Q | 2Q | 3Q | 4Q |
| 2026 | 2.11E | 2.42E | 2.48E | |
| 2025 | 1.81A | 2.19A | 2.40A | 2.25E |
| 2024 | 1.50A | 1.75A | 1.84A | 2.21A |
*Aggressive/Moderate/Conservative labels describe broad business characteristics for educational purposes only. They are not risk ratings, investment guidance, or recommendations. A = Actual, E = Estimated. Market metrics such as beta, valuation multiples, and analyst estimates are widely referenced in financial research. Their relevance depends on an individual’s goals, time horizon, and risk tolerance. These figures are for informational purposes only and should not be interpreted as predictions or guidance.
Keys for Success
Intuitive Surgical’s robot-based da Vinci surgical system has been a key driver for the company’s performance since its launch in 1999. The company’s continued focus on upgrading the system has played a pivotal role in sustaining its growth. The system’s minimally invasive nature has enabled its broad adoption for specific surgical procedures.
The company installed 427 new da Vinci systems during the quarter, 240 of which were next-generation da Vinci 5 systems. That da Vinci 5 figure is more than double what Intuitive put into place in the third quarter of 2024, and it’s encouraging to see customers paying up for the company’s latest technology.
While the sale of the da Vinci system can be time-consuming and inconsistent due to its high price, the sale of accessories provides the company with a recurring revenue stream that accounts for the majority of its revenue. Recurring revenue accounted for 85% of total sales in the first half of 2025, highlighting the significance of instruments and accessories (I&A). I&A revenue per procedure held steady at nearly $1,780–$1,800.
Intuitive Surgical has reported a recovery in procedures since February 2023, following a decline in COVID-related infections and hospitalizations. The recovery in procedures continued through 2024 and 2025.
The company is increasingly embedding AI and digital tools into its robotic ecosystem. Case Insights, integrated into da Vinci 5, combines surgical video with force and motion data, enabling objective performance indicators for surgeons.
The company reported revenues of $2.51 billion, up 23% year over year, and 3Q 2025 adjusted earnings per share of $2.40. The bottom line improved 30.4% year over year.
Keys for Concern
Despite strong demand, Intuitive Surgical’s supply chain pressures continue to weigh on margins. The company also faces increasing competition in the robotic-assisted surgery market. While the da Vinci system had limited direct competition for many years, other companies, including Johnson & Johnson and Medtronic, are now developing alternative robotic solutions.
Mark Notes
The adoption and increasing use of robotics is becoming a new investment theme for investors. Growing adoption of the company’s da Vinci system, increasing procedure volumes, continuous innovation, and a solid recurring revenue base are key catalysts. Intuitive Surgical’s devices are on the cutting edge of this trend.
New to investing? These explanations may help:
• Understanding Earnings Season
• Risk Categories & Diversification
This article is for general informational and educational purposes only. It is not intended as financial advice, investment guidance, or a recommendation to buy or sell any security. The content reflects publicly available information and broad market commentary. Readers should conduct their own research and consult a licensed financial professional before making investment decisions.